Jump to content

PeproMene Bio, Inc. gab den Abschluss der ersten Dosis-Kohorte und den Beginn der zweiten Dosis-Kohorte in der klinischen Phase-1-Studie mit PMB-CT01 (BAFFR-CAR T-Zellen) für das B-Zell-Non-Hodgkin-Lymphom (B-NHL) bekannt


In The News

Recommended Posts

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now


×
×
  • Create New...